Previous 10 | Next 10 |
Initial Clinical Data Show RTX-240 Stimulates Innate and Adaptive Immunity (NK Cells and T Cells) Supporting Proof of Mechanism – Additional Results to be Presented in Early 2021 IND Cleared and Patient Screening Underway for Phase 1 Clinical Trial of RTX-321 in Advanced Hu...
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announced ...
Gainers: Anchiano Therapeutics (ANCN) +142%.BioCardia (BCDA) +87%.Prevail Therapeutics (PRVL) +81%.Solid Biosciences (SLDB) +36%.OncoCyte (OCX) +24%.Bridgetown (BTWN) +23%.Contango Oil & Gas (MCF) +22%.Immutep (IMMP) +22%.MicroVision (MVIS) +20%.Sio Gene Therapies (SIOX) +1...
Gainers: Anchiano Therapeutics ANCN +173%, Prevail Therapeutics PRVL +84%, BioCardia (BCDA) +40%, Solid Biosciences (SLDB) +37%, OncoCyte OCX +32%.Losers: Mirum Pharmaceuticals (MIRM) -21%, Mesoblast (MESO) -18%, Rubius Therapeutics ...
Palm Beach, FL – December 15, 2020 – While the pharmaceutical industry has had an amazing record of developing therapeutic drugs for countless uses, sometimes, a remaining part of the problem is how do you get the drug into the patient’s body? The simplest way is usuall...
Gainers: [[MDWD]] +19.5%. [[KZR]] +14.3%. [[PQG]] +9%. [[GOSS]] +4%. [[RC]] +2.6%.Losers: [[MESO]] -7.6%. [[CELP]] -5.3%. [[GDS]] -5.1%. [[EAF]] -4.2%. [[RUBY]] -4%. For further details see: MESO, EAF, RC and MDWD among after-hours movers
Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...
Gainers: Arvinas (ARVN) +97%, Rubius Therapeutics (RUBY) +95%, AnPac Bio-Medical Science (ANPC) +67%, Veru (VERU) +46%, BioCardia (BCDA) +31%.Losers: Aerpio Pharmaceuticals (ARPO) -47%, SELLAS Life Sciences (SLS) -27%, Greenwich Life...
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...
CAMBRIDGE, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced...
News, Short Squeeze, Breakout and More Instantly...
Rubius Therapeutics Inc. Company Name:
RUBY Stock Symbol:
OTCMKTS Market:
Rubius Therapeutics Inc. Website:
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...